Author

M. R. D'Agostino

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

M. S. Miller· 3 shared A. Zhang· 2 shared J. C. Ang· 2 shared S. Afkhami· 2 shared A. A. Ashkar· 1 shared A. Banerjee· 1 shared A. C. Doxey· 1 shared A. G. McArthur· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

M. S. Miller

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologyPLOS PathogensPeer-reviewedJun 29, 2023

Targeting the MR1-MAIT Cell Axis Improves Vaccine Efficacy and Affords Protection against Viral Pathogens

R. Rashu, M. Ninkov, C. M. Wardell…·S. M. M. Haeryfar

This study shows that targeting the MR1-MAIT cell axis with 5-OP-RU enhances vaccine efficacy against viral pathogens by expanding and reprogramming MAIT cells.

DOI 10.1371/journal.ppat.1011485

mousehuman

𝕏 PostBluesky

ImmunologybioRxivJul 16, 2021

Single-dose respiratory mucosal delivery of next-generation viral-vectored COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

S. Afkhami, M. R. D'Agostino, A. Zhang…·Z. Xing

This study evaluates a multivalent Ad-vectored vaccine delivered via respiratory mucosal route, showing robust protection against SARS-CoV-2 and variants in mice.

DOI 10.1016/j.cell.2022.02.005

mouseexperimental assay

𝕏 PostBluesky

ImmunologybioRxivJun 18, 2020

Experimental and natural evidence of SARS-CoV-2 infection-induced activation of type I interferon responses

A. Banerjee, N. El-Sayes, P. Budylowski…·K. Mossman

This study shows SARS-CoV-2 infection induces a mild type I IFN response in vitro and in moderate COVID-19 cases, and cannot inhibit exogenous IFN induction.

DOI 10.1016/j.isci.2021.102477

humanbulk RNA-seq

𝕏 PostBluesky